"With nearly 35 years experience in the financial services andbiotechnology sectors, Lou Drapeau is an experienced financial executive withan impressive track record of successfully leading life science companiestoward achievement of their business objectives," said Dan Welch, Presidentand Chief Executive Officer of InterMune. "We look forward to drawing on hisexceptional experience as we focus our resources on advancing our excitingpulmonology and hepatology research and development programs."
Advertisement
Most Recently, Mr. Drapeau served as Senior Vice President, Finance andChief Financial Officer for Nektar Therapeutics from January 2006 to August2007. From August 2002 to August 2005, Mr. Drapeau held the position ofSenior Vice President and Chief Financial Officer at BioMarin PharmaceuticalInc., a biotechnology company. Mr. Drapeau also served as Acting ChiefExecutive Officer of BioMarin from August 2004 to May 2005.
Advertisement
He previously spent more than 30 years with public accounting firm ArthurAndersen, including 19 years as an Audit Partner in Arthur Andersen's NorthernCalifornia Audit and Business Consulting practice and 12 years as managingpartner.
Mr. Drapeau holds an undergraduate degree in mechanical engineering and amaster's in business administration from Stanford University.
About InterMune
InterMune is a biotechnology company focused on the research, developmentand commercialization of innovative therapies in pulmonology and hepatology.InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis(IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolioincludes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as apossible therapeutic candidate for the treatment of patients with IPF and aresearch program focused on small molecules for pulmonary disease. Thehepatology portfolio includes the HCV protease inhibitor compound ITMN-191(referred to as R7227 within the Roche research and development programs) inPhase 1a, a second-generation HCV protease inhibitor research program, and aresearch program evaluating a new target in hepatology. For additionalinformation about InterMune and its R&D pipeline, please visithttp://www.intermune.com.
Forward-Looking Statements
This news release contains forward-looking statements within the meaningof section 21E of the Securities Exchange Act of 1934, as amended, thatreflect InterMune's judgment and involve risks and uncertainties as of thedate of this release. All forward-looking statements and other informationincluded in this press release are based on information available to InterMuneas of the date hereof, and InterMune assumes no obligation to update any suchforward-looking statements or information. InterMune's actual results coulddiffer materially from those described in InterMune's forward-lookingstatements.
Factors that could cause or contribute to such differences include, butare not limited to, those discussed in detail under the heading "Risk Factors"in InterMune's most recent annual report on Form 10-K filed with the SEC onMarch 30, 2007 (the "Form 10-K") and other periodic reports filed with theSEC, all of which are available via InterMune's web site athttp://www.intermune.com.
SOURCE InterMune, Inc.
